CALMA B Stock Overview
Calmark Sweden AB (publ) operates as a medical technology company in Sweden and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Calmark Sweden AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 0.098 |
52 Week High | SEK 1.10 |
52 Week Low | SEK 0.074 |
Beta | 1.49 |
11 Month Change | -3.37% |
3 Month Change | -14.39% |
1 Year Change | -80.48% |
33 Year Change | -98.81% |
5 Year Change | n/a |
Change since IPO | -98.05% |
Recent News & Updates
Recent updates
Shareholder Returns
CALMA B | SE Medical Equipment | SE Market | |
---|---|---|---|
7D | -2.9% | -4.0% | -4.3% |
1Y | -80.5% | -0.002% | 12.6% |
Return vs Industry: CALMA B underperformed the Swedish Medical Equipment industry which returned -7.9% over the past year.
Return vs Market: CALMA B underperformed the Swedish Market which returned 6.9% over the past year.
Price Volatility
CALMA B volatility | |
---|---|
CALMA B Average Weekly Movement | 21.9% |
Medical Equipment Industry Average Movement | 7.1% |
Market Average Movement | 5.8% |
10% most volatile stocks in SE Market | 12.2% |
10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: CALMA B's share price has been volatile over the past 3 months.
Volatility Over Time: CALMA B's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 4 | Camilla Arneving | www.calmark.se |
Calmark Sweden AB (publ) operates as a medical technology company in Sweden and internationally. The company manufactures and sells POC-Analyzer, a reader with a built-in software, analyzes the color change that occurs in the test cassette; and Neo-Bilirubin, a test cassette with a patented filter design that separates the red blood cells from the plasma used in the POC-Analyzer. It also provides a POC test solution for assessing the severity of COVID-19.
Calmark Sweden AB (publ) Fundamentals Summary
CALMA B fundamental statistics | |
---|---|
Market cap | SEK 11.03m |
Earnings (TTM) | -SEK 22.23m |
Revenue (TTM) | SEK 136.00k |
81.1x
P/S Ratio-0.5x
P/E RatioIs CALMA B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CALMA B income statement (TTM) | |
---|---|
Revenue | SEK 136.00k |
Cost of Revenue | SEK 1.07m |
Gross Profit | -SEK 938.00k |
Other Expenses | SEK 21.30m |
Earnings | -SEK 22.23m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.20 |
Gross Margin | -689.71% |
Net Profit Margin | -16,348.53% |
Debt/Equity Ratio | 0% |
How did CALMA B perform over the long term?
See historical performance and comparison